BACKGROUND: The treatment of isolated liver metastases has become a rapidly developing field with many new, technically advanced methods. Here we present the therapeutic efficacy of a robotic radiosurgery for local control of liver metastases from solid tumors. METHODS: Patients with tumorous lesions to the liver, not qualifying for surgery, were treated with single-session radiosurgery (24 Gy) that used robotic image-guided real-time tumor tracking. All detectable lesions had to be irradiated. In a prospective analysis, follow-up was performed by magnetic resonance imaging scanning 2 months after the treatment, and subsequently at 3-month intervals to evaluate local control. For inclusion into the radiosurgery treatment protocol, tumor volumes had to be <90 ml. RESULTS: Thirty-six patients (median age, 65 years) with a total of 54 target lesions were evaluated. Single lesions were treated in 23 patients and multiple targets in 13 patients. Metastases originated from colon cancer (n = 19), ovarian cancer (n = 3), pancreatic cancer (n = 2), breast cancer (n = 2), and others (n = 6). Four lesions were of primary liver origin (hepatocellular carcinoma and cholangiocellular carcinoma). Median tumor volume was 18 ml (range, 2.2-90 ml). The median follow-up was 21.3 months. The disease of 25 patients (69.4%) showed complete or partial local response, 6 patients (16.7%) had stable lesions, and 5 patients (14%) experienced local recurrence. Grade 2-4 adverse events due to radiation treatment were not observed. CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver neoplasm is a new and promising approach for patients with disease that is not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.
BACKGROUND: The treatment of isolated liver metastases has become a rapidly developing field with many new, technically advanced methods. Here we present the therapeutic efficacy of a robotic radiosurgery for local control of liver metastases from solid tumors. METHODS:Patients with tumorous lesions to the liver, not qualifying for surgery, were treated with single-session radiosurgery (24 Gy) that used robotic image-guided real-time tumor tracking. All detectable lesions had to be irradiated. In a prospective analysis, follow-up was performed by magnetic resonance imaging scanning 2 months after the treatment, and subsequently at 3-month intervals to evaluate local control. For inclusion into the radiosurgery treatment protocol, tumor volumes had to be <90 ml. RESULTS: Thirty-six patients (median age, 65 years) with a total of 54 target lesions were evaluated. Single lesions were treated in 23 patients and multiple targets in 13 patients. Metastases originated from colon cancer (n = 19), ovarian cancer (n = 3), pancreatic cancer (n = 2), breast cancer (n = 2), and others (n = 6). Four lesions were of primary liver origin (hepatocellular carcinoma and cholangiocellular carcinoma). Median tumor volume was 18 ml (range, 2.2-90 ml). The median follow-up was 21.3 months. The disease of 25 patients (69.4%) showed complete or partial local response, 6 patients (16.7%) had stable lesions, and 5 patients (14%) experienced local recurrence. Grade 2-4 adverse events due to radiation treatment were not observed. CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver neoplasm is a new and promising approach for patients with disease that is not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.
Authors: Nicolaus Andratschke; Alan Parys; Susanne Stadtfeld; Stefan Wurster; Stefan Huttenlocher; Detlef Imhoff; Müjdat Yildirim; Dirk Rades; Claus Michael Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck Journal: Radiat Oncol Date: 2016-05-28 Impact factor: 3.481
Authors: Michael I Lock; Jonathan Klein; Hans T Chung; Joseph M Herman; Edward Y Kim; William Small; Nina A Mayr; Simon S Lo Journal: World J Hepatol Date: 2017-05-18
Authors: N Andratschke; H Alheid; M Allgäuer; G Becker; O Blanck; J Boda-Heggemann; T Brunner; M Duma; S Gerum; M Guckenberger; G Hildebrandt; R J Klement; V Lewitzki; C Ostheimer; A Papachristofilou; C Petersen; T Schneider; R Semrau; S Wachter; D Habermehl Journal: BMC Cancer Date: 2018-03-13 Impact factor: 4.430
Authors: Sebastian Stintzing; Jobst von Einem; Christoph Fueweger; Alfred Haidenberger; Michael Fedorov; Alexander Muavcevic Journal: Cancer Res Treat Date: 2018-04-16 Impact factor: 4.679
Authors: Jobst C Von Einem; Sebastian Stintzing; Dominik P Modest; Michael Wiedemann; Christoph Fürweger; Alexander Muacevic Journal: Cureus Date: 2020-03-18
Authors: Markus Schoenberg; Andrey Khandoga; Sebastian Stintzing; Christoph Trumm; Tobias Simon Schiergens; Martin Angele; Mark Op den Winkel; Jens Werner; Alexander Muacevic; Markus Rentsch Journal: Cureus Date: 2016-04-28